PB 64 of 2014
National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2014 (No. 8)
National Health Act 1953
___________________________________________________________________________
I, Kim Bessell, Assistant Secretary, Pharmaceutical Access Branch, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health, make this instrument under subsections 100(1) and (2) of the National Health Act 1953.
Dated 19 August 2014
KIM BESSELL
Assistant Secretary
Pharmaceutical Access Branch
Principal Pharmacy Advisor
Pharmaceutical Benefits Division
Department of Health
___________________________________________________________________
1 Name of Instrument
(1) This Instrument is the National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2014 (No.8).
(2) This Instrument may also be cited as PB 64 of 2014.
2 Commencement
This Instrument commences on 1 September 2014.
3 Amendments to PB 79 of 2011
Schedule 1 amends the National Health (Efficient Funding of Chemotherapy) Special Arrangement 2011 (PB 79 of 2011).
Schedule 1 Amendments
[1] Schedule 1 Part 1 entry for ‘Carboplatin’ in each of the forms ‘Solution for I.V. injection 150 mg in 15 mL’; ‘Solution for I.V. injection 450 mg in 45 mL’; and ‘Solution for I.V. injection 50 mg in 5 mL’ with manner of administration Injection:
omit :
Carboplatin Ebewe
SZ
MP
D
[2] Schedule 1 Part 1, entry for ‘Epirubicin’ in the form ‘Solution for injection containing epirubicin hydrochloride 200 mg in 100 mL’ with manner of administration Injection/Intravesical:
omit from the column headed ‘Brand’: Epirubicin Actavis 200 substitute: Epirubicin ACT
omit from the column headed ‘Responsible Person’: UA substitute: VN
[3] Schedule 1 Part 1, entry for ‘Epirubicin’ in the form ‘Solution for injection containing epirubicin hydrochloride 50 mg in 25 mL’ with manner of administration Injection/Intravesical:
omit from the column headed ‘Brand’: Epirubicin Actavis 50 substitute: Epirubicin ACT
omit from the column headed ‘Responsible Person’: UA substitute: VN
[4] Schedule 1 Part 1 after the entry for ‘Fludarabine’ in the form ‘Powder for I.V. injection containing fludarabine phosphate 50 mg’ with manner of administration Injection and Brand ‘Fludara’:
insert :
Fludarabine ACT
VN
MP
3887
D
[5] Schedule 1 Part 1 after the entry for ‘Gemcitabine’ in the form ‘Powder for I.V. infusion 200 mg (as hydrochloride)’ with manner of administration Injection:
omit :
Solution concentrate for I.V. infusion 1 g
(as hydrochloride) in 25 mL
Injection
Gemcitabine Ebewe
SZ
MP
D
[6] Schedule 1 Part 1 after the entry for ‘Gemcitabine’ in the form ‘Solution concentrate for I.V. infusion 1000 mg (as hydrochloride) in 100 mL’ with manner of administration Injection:
omit :
Solution concentrate for I.V. infusion 2 g
(as hydrochloride) in 50 mL
Injection
Gemcitabine Ebewe
SZ
MP
D
Solution concentrate for I.V. infusion 200 mg
(as hydrochloride) in 5 mL
Injection
Gemcitabine Ebewe
SZ
MP
D
[7] Schedule 1 Part 1 entry for ‘Irinotecan’ in the form ‘I.V injection containing irinotecan hydrochloride trihydrate 100 mg in 5 mL’ with manner of administration Injection:
omit :
Irinotecan SZ
HX
MP
D
[8] Schedule 1 Part 1 entry for ‘Oxaliplatin’ in each of the forms ‘Powder for I.V. infusion 100 mg’; and ‘Powder for I.V. infusion 50 mg’ with manner of administration Injection:
omit :
Oxaliplatin Alphapharm
AF
MP
D
[9] Schedule 2 after the entry for ‘Ondansetron’ in each of the forms ‘Tablet 4 mg (as hydrochloride dihydrate)’; and ‘Tablet 8 mg (as hydrochloride dihydrate)’ with manner of administration Oral and Brand ‘APO‑Ondansetron’:
insert :
Ondansetron AN
EA
EMP
C3050
4
0
[10] Schedule 2 after the entry for ‘Ondansetron’ in each of the forms ‘Tablet (orally disintegrating) 4 mg’; and ‘Tablet (orally disintegrating) 8 mg’ with manner of administration Oral:
insert :
Ondansetron AN ODT
EA
EMP
C3050
4
0
[11] Schedule 3, Responsible Person codes, after entry for BX:
insert:
EA
Amneal Pharmaceuticals Pty Ltd
21 147 854 484
